explore -WSS

explore

author：Wikipedia 2025-10-02 19:15:43 - browse：753

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

WSS

Readers respond to H5N1 and livestock movements, and more

To avoid data mishandling cases, universities eye AI and other tools

It's time to retire 'poor historian' from clinicians' vocabularies

KalVista pill reduced swelling 'attacks' caused by genetic disease

Data integrity in scientific journals requires "effort" by publishers, institutions

Solving academic medical centers' existential crisis

hotspot

explore

focus

Supreme Court strikes down use of affirmative action

PhRMA lawsuit over Medicare drug price negotiation tossed

23andMe had bad news about my health. I wish a person had delivered it

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Cancer drug shortages should be causing more outrage

Medical mystery: When a cough is not just a cough

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Helping hospitals and community health centers plan for resilience

leisure time

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Addiction experts warn against a second 'war on drugs'

NVIDIA and Google execs on the future of AI and drug discovery

KalVista pill reduced swelling 'attacks' caused by genetic disease

What we’ve learned from the Aduhelm mess

Glen Campbell's doctor discusses his public struggle with Alzheimer's

hotspot

focus

knowledge

hotspot